/DVHGF
DVHGF Stock - Devonian Health Group Inc.
Healthcare|BiotechnologyOTC
$0.07+0.00%
+$0.00 (+0.00%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.08
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DVHGF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.07 – $0.07
TARGET (TP)$0.08
STOP LOSS$0.07
RISK/REWARD1:8.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.21
52W High$0.18
52W Low$0.07
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $17.03M | $17.82M | $2.35M | $2.31M | $1.47M |
| Gross Profit | $8.56M | $5.99M | $892,341 | $561,015 | $-240,902 |
| Gross Margin | 50.3% | 33.6% | 38.0% | 24.3% | -16.3% |
| Operating Income | $-1,027,425 | $-858,442 | $-4,283,427 | $-2,912,566 | $-2,305,961 |
| Net Income | $-4,339,852 | $-1,224,636 | $-4,599,607 | $-3,448,302 | $-3,346,380 |
| Net Margin | -25.5% | -6.9% | -196.1% | -149.6% | -226.9% |
| EPS | $-0.03 | $-0.01 | $-0.03 | $-0.03 | $-0.04 |
Company Overview
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
DVHGFBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q4 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 9, 2026 | — | — | — | — |
Q4 2025 | Dec 11, 2025 | — | $-0.00 | — | — |
Q2 2025 | Jun 26, 2025 | — | $-0.02 | — | — |
Q2 2025 | Apr 15, 2025 | — | $-0.00 | — | — |
Q4 2024 | Dec 20, 2024 | — | $-0.00 | — | — |
Q4 2024 | Nov 29, 2024 | — | $0.01 | — | — |
Q2 2024 | Jun 25, 2024 | — | $-0.00 | — | — |
Q1 2024 | Mar 27, 2024 | — | $-0.01 | — | — |
Q4 2023 | Dec 22, 2023 | — | $-0.00 | — | — |
Q4 2023 | Nov 28, 2023 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.01 | — | — |
Q2 2023 | Apr 30, 2023 | — | $-0.01 | — | — |
Q4 2022 | Dec 22, 2022 | — | $-0.00 | — | — |
Q4 2022 | Oct 31, 2022 | — | $-0.01 | — | — |
Q2 2022 | Apr 30, 2022 | — | $-0.00 | — | — |
Q1 2022 | Jan 31, 2022 | — | $-0.01 | — | — |
Q4 2021 | Oct 31, 2021 | — | $-0.01 | — | — |
Q3 2021 | Jul 31, 2021 | — | $-0.01 | — | — |
Q2 2021 | Apr 30, 2021 | — | $-0.01 | — | — |
Q1 2021 | Jan 31, 2021 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about DVHGF
What is DVHGF's current stock price?
Devonian Health Group Inc. (DVHGF) is currently trading at $0.07 per share. The stock has moved +0.00% today.
What is the analyst price target for DVHGF?
No analyst price targets are currently available for this stock.
What sector is Devonian Health Group Inc. in?
Devonian Health Group Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is DVHGF's market cap?
Devonian Health Group Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does DVHGF pay dividends?
No, Devonian Health Group Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorECGS
Eco-Growth Strategies Inc.
$0.20
Mkt Cap: $0.0B
HMTXF
Hemostemix Inc.
$0.06
Mkt Cap: $0.0B
HOOK
HOOKIPA Pharma Inc.
$0.88
Mkt Cap: $0.0B
IMUC
EOM Pharmaceuticals Holdings, Inc.
$0.15
Mkt Cap: $0.0B
INTI
Inhibitor Therapeutics, Inc.
$0.04
Mkt Cap: $0.0B
LVCLF
Algorae Pharmaceuticals Limited
$0.00
Mkt Cap: $0.0B
NYMXF
Nymox Pharmaceutical Corporation
$0.07
Mkt Cap: $0.0B
OXBOF
Oxford BioDynamics Plc
$0.00
Mkt Cap: $0.0B
SPLTF
SpotLite360 IOT Solutions, Inc.
$0.08
Mkt Cap: $0.0B
UDOCF
Unidoc Health Corp.
$0.13
Mkt Cap: $0.0B
Explore stocks similar to DVHGF for comparison